Acute Myeloid Leukemia [clinicaltrials_resource:69608347e3f7b9ef49ed5f7a6fe0a518]
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00037583]Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia [clinicaltrials:NCT00037596]Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies [clinicaltrials:NCT00038051]clinicaltrials:NCT00045942Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older [clinicaltrials:NCT00048503]clinicaltrials:NCT00067028Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00079482]clinicaltrials:NCT00081822Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00086099]clinicaltrials:NCT00088218Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers [clinicaltrials:NCT00089596]Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00093990]Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide [clinicaltrials:NCT00125606]Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies [clinicaltrials:NCT00143559]clinicaltrials:NCT00145626Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result [clinicaltrials:NCT00146120]clinicaltrials:NCT00150878Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00151242]All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00151255]WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00153582]Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel [clinicaltrials:NCT00159003]Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care [clinicaltrials:NCT00161668]Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image [clinicaltrials:NCT00172562]clinicaltrials:NCT00186966clinicaltrials:NCT00187096Early Allogeneic Blood Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00188136]Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS [clinicaltrials:NCT00195000]Efficacy of G-CSF-Priming in Elderly AML Patients [clinicaltrials:NCT00199147]To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning [clinicaltrials:NCT00226512]clinicaltrials:NCT00235560T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) [clinicaltrials:NCT00242515]clinicaltrials:NCT00255346clinicaltrials:NCT00260832Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) [clinicaltrials:NCT00266136]Amonafide in Combination With Cytarabine in Secondary AML [clinicaltrials:NCT00273884]clinicaltrials:NCT00276159Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia [clinicaltrials:NCT00279773]A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [clinicaltrials:NCT00283114]A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. [clinicaltrials:NCT00300664]clinicaltrials:NCT00309842
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT00660166 [clinicaltrials_resource:1786032b4154028328a3baf181228dd6]eligibility for clinicaltrials:NCT01683123 [clinicaltrials_resource:2051118b70bdbf7ed90e399f00e7ae35]eligibility for clinicaltrials:NCT01622556 [clinicaltrials_resource:45f4e00e18f98d4454588424ee095200]eligibility for clinicaltrials:NCT01142375 [clinicaltrials_resource:5748206ab670836930cf62e22af970ec]eligibility for clinicaltrials:NCT01685606 [clinicaltrials_resource:fa2e28c270d1c972b26991fff7ab54fc]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00660166 [clinicaltrials_resource:1786032b4154028328a3baf181228dd6]eligibility for clinicaltrials:NCT01683123 [clinicaltrials_resource:2051118b70bdbf7ed90e399f00e7ae35]eligibility for clinicaltrials:NCT01622556 [clinicaltrials_resource:45f4e00e18f98d4454588424ee095200]eligibility for clinicaltrials:NCT01142375 [clinicaltrials_resource:5748206ab670836930cf62e22af970ec]eligibility for clinicaltrials:NCT01685606 [clinicaltrials_resource:fa2e28c270d1c972b26991fff7ab54fc]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Acute Myeloid Leukemia [clinicaltrials_resource:69608347e3f7b9ef49ed5f7a6fe0a518]
Bio2RDF identifier
69608347e3f7b9ef49ed5f7a6fe0a518
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:69608347e3f7b9ef49ed5f7a6fe0a518
identifier
clinicaltrials_resource:69608347e3f7b9ef49ed5f7a6fe0a518
title
Acute Myeloid Leukemia
@en
label
Acute Myeloid Leukemia [clinicaltrials_resource:69608347e3f7b9ef49ed5f7a6fe0a518]
@en